| abstract |
Disclosed in the present invention is a multi-component gel sustained-release pharmaceutical composition for the treatment of tumors, characterized by comprising active components and auxiliary materials, wherein the active components comprise a chemotherapy drug, an immune adjuvant or an immune checkpoint inhibitor causing the immunogenic death of tumor cells; the auxiliary materials comprise a gel-forming matrix and a buffer liquid; the gel-forming matrix comprises one or more of serum albumin, fibrinogen, sodium alginate, calcium alginate, collagen, chitosan, butyl glycan, gelatin, starch, hyaluronic acid, sodium carboxymethyl cellulose, sodium glycerophosphate, cyanoacrylate, acrylamide, polyoxyethylene, polyethylene glycol, polyvinyl alcohol, poloxamer, polycaprolactone, and steroid compounds. A method for preparing the sustained-release gel is simple, and the gel prepared can slowly release a drug, which effectively enhances the synergy of the drug, thereby having good application prospects in the field of resisting tumors. |